Novo Nordisk intensified its campaign against copycat versions of its obesity and diabetes medicines, filing 14 additional U.S. lawsuits that target pharmacies and telehealth companies accused of selling non-FDA-approved compounded semaglutide under the guise of personalised treatment. The new cases lift the Danish drugmaker’s total semaglutide-related filings to 132 across 40 states, with courts having already issued 44 permanent injunctions. The legal escalation coincided with second-quarter results that fell short of market expectations. Net sales rose 13% year-on-year to DKK 76.9 billion ($11.9 billion) and operating profit reached DKK 33.4 billion, both marginally below analyst estimates. Sales of Wegovy jumped 67% to DKK 19.5 billion, yet overall quarterly growth was the slowest in four years as the company ceded U.S. market share to Eli Lilly’s rival therapy and to compounded copycats. Chief Financial Officer Karsten Munk Knudsen told analysts that more than one million U.S. patients continue to use compounded GLP-1 products and that Novo Nordisk’s full-year outlook assumes no near-term reduction in that market. He also warned that Ozempic prices in the United States are likely to decline by 2026, and said the company is preparing cost cuts that could include job reductions. Outgoing Chief Executive Lars Fruergaard Jorgensen said Novo Nordisk is in active talks with the Trump administration on lowering U.S. prices for Wegovy and is expanding its NovoCare direct-to-consumer platform to reach cash-paying patients. The company’s shares have come under additional pressure from a UBS downgrade and a class-action lawsuit by investors who allege it overstated growth prospects.